Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Tablets × Genitourinary × Clear all

Phase

Phase 3 2 Phase NA 1 Phase EARLY_PHASE1 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11 Other hematologic neoplasm 5 Lymphoid 4 Gastrointestinal 4 Plasma cell 3 Dermatologic 3 Myeloid 2 Thoracic 1 Other 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Classical hematology 1 CNS 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 168 Gemcitabine 126 Prednisone 125 pembrolizumab 102 enzalutamide 100 Abiraterone Acetate 92 Nivolumab 86 Magnetic Resonance Spectroscopy 86 Cisplatin 86 Leuprolide 81 Radiotherapy 79 Sunitinib 77 Carboplatin 73 Specimen Handling 61 Radiosurgery 56 Paclitaxel 54 Goserelin 53 Androgen Antagonists 50 bicalutamide 49 Ipilimumab 49 apalutamide 47 Bevacizumab 44 Sorafenib 43 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 42 cabozantinib 40 cabazitaxel 40 Everolimus 40 abiraterone 39 atezolizumab 35 Axitinib 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05265988 2024-07-31

MERIDIAN

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Phase 2 Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡